Leonard S. Schleifer

Board co-Chair, President and Chief Executive Officer · Regeneron Pharmaceuticals

Biopharmaceuticals

Leonard S. Schleifer is board co-chair, president and chief executive officer of Regeneron Pharmaceuticals. A physician and scientist, he founded the company in 1988 and has led its development from a biotechnology startup into a drug discovery, development and commercialization business.

Last reviewed: Oct 21, 2026

Leonard S. Schleifer

Board co-Chair, President and Chief Executive Officer Regeneron Pharmaceuticals

Last Reviewed: October 21, 2026

Executive Summary

Leonard S. Schleifer is board co-chair, president and chief executive officer of Regeneron Pharmaceuticals. A physician and scientist, he founded the company in 1988 and has led its development from a biotechnology startup into a drug discovery, development and commercialization business.

Career Highlights

  • Founded Regeneron in 1988 and has served as its chief executive since inception.
  • Became board co-chair in 2023 alongside George Yancopoulos.
  • Named Cornell Entrepreneur of the Year in 2019 and elected an AAAS fellow that year.

Professional Journey

Schleifer trained as a physician and pharmacologist before entering biotechnology. He worked as a neurologist and professor at Cornell Medical School, where the limited treatments available for serious neurological conditions helped motivate his interest in building a research company.

He founded Regeneron in 1988 and recruited George Yancopoulos from Columbia University to lead its scientific work. Their partnership combined company building with a sustained investment in internally developed drug discovery technologies. Schleifer has remained president and chief executive throughout that development and became board co-chair in 2023.

His current responsibilities sit at the intersection of corporate leadership and scientific strategy. Regeneron’s company biography describes a research portfolio extending from eye disease and allergic inflammation to cancer, cardiovascular conditions and rare diseases. The organization’s response to infectious disease emergencies also reflects its investment in antibody technologies. These are company programs rather than medicines credited solely to one executive.

Schleifer has supported the company’s investment in science education and its broader corporate responsibility efforts. Cornell recognized his entrepreneurial career in 2019, when he discussed persistence, scientific partnerships and learning from more experienced colleagues with students and founders. His company biography also records his election as an American Association for the Advancement of Science fellow in 2019.

Education

Schleifer earned his undergraduate degree at Cornell University, where he majored in biological sciences. He holds an MD and a PhD in pharmacology from the University of Virginia.